Close
Blog & Resources Camargo Blog September 23rd, 2008

Another DESI in Discretion

Ever since FDA gave notice about Marketed Unapproved Drugs, manufacturers of these drugs have been wondering when the shoe would drop on their products. Basically, the FDA has said that eventually these products must be removed from the market. Since the FDA does not have sufficient resources, it will remove products it deems most hazardous. Once FDA decides to remove a product from the market, all manufacturers will need to discontinue the product.

The FDA informs the manufacturers via a Federal Register Notice. Today, 9/23/2008, FDA notified manufacturers of ophthalmic balanced salt solution that it will take enforcement action against this product manufactured after November 24, 2008 or shipped after January 21, 2008. Apparently, this drug product made the priority list due to safety concerns.

The caveat is that if the FDA observes significant cGMP issues at a manufacturer, it can determine to take immediate action against that manufacturer’s DESI product. Such action would allow other manufacturers to continue until FDA takes action against the product itself.


Categories: DESI Drug

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road,
Suite 203
Cincinnati, OH 45242
Durham Office
2505 Meridian Parkway,
Suite 150
Durham, NC 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights